196 related articles for article (PubMed ID: 25895168)
1. Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma.
Carlucci G; Carney B; Brand C; Kossatz S; Irwin CP; Carlin SD; Keliher EJ; Weber W; Reiner T
Mol Imaging Biol; 2015 Dec; 17(6):848-55. PubMed ID: 25895168
[TBL] [Abstract][Full Text] [Related]
2. Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models.
Carney B; Carlucci G; Salinas B; Di Gialleonardo V; Kossatz S; Vansteene A; Longo VA; Bolaender A; Chiosis G; Keshari KR; Weber WA; Reiner T
Mol Imaging Biol; 2016 Jun; 18(3):386-92. PubMed ID: 26493053
[TBL] [Abstract][Full Text] [Related]
3. PARPi-FL--a fluorescent PARP1 inhibitor for glioblastoma imaging.
Irwin CP; Portorreal Y; Brand C; Zhang Y; Desai P; Salinas B; Weber WA; Reiner T
Neoplasia; 2014 May; 16(5):432-40. PubMed ID: 24970386
[TBL] [Abstract][Full Text] [Related]
4. Radioiodinated PARP1 tracers for glioblastoma imaging.
Salinas B; Irwin CP; Kossatz S; Bolaender A; Chiosis G; Pillarsetty N; Weber WA; Reiner T
EJNMMI Res; 2015 Dec; 5(1):123. PubMed ID: 26337803
[TBL] [Abstract][Full Text] [Related]
5. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
[TBL] [Abstract][Full Text] [Related]
6. Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[
Demétrio de Souza França P; Roberts S; Kossatz S; Guru N; Mason C; Zanoni DK; Abrahão M; Schöder H; Ganly I; Patel SG; Reiner T
Nucl Med Biol; 2020; 84-85():80-87. PubMed ID: 32135475
[TBL] [Abstract][Full Text] [Related]
7. Safety and Feasibility of PARP1/2 Imaging with
Schöder H; França PDS; Nakajima R; Burnazi E; Roberts S; Brand C; Grkovski M; Mauguen A; Dunphy MP; Ghossein RA; Lyashchenko SK; Lewis JS; O'Donoghue JA; Ganly I; Patel SG; Lee NY; Reiner T
Clin Cancer Res; 2020 Jul; 26(13):3110-3116. PubMed ID: 32245901
[TBL] [Abstract][Full Text] [Related]
8. PARP1-targeted fluorescence molecular endoscopy as novel tool for early detection of esophageal dysplasia and adenocarcinoma.
Marcazzan S; Braz Carvalho MJ; Nguyen NT; Strangmann J; Slotta-Huspenina J; Tenditnaya A; Tschurtschenthaler M; Rieder J; Proaño-Vasco A; Ntziachristos V; Steiger K; Gorpas D; Quante M; Kossatz S
J Exp Clin Cancer Res; 2024 Feb; 43(1):53. PubMed ID: 38383387
[TBL] [Abstract][Full Text] [Related]
9. Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent.
Kossatz S; Brand C; Gutiontov S; Liu JT; Lee NY; Gönen M; Weber WA; Reiner T
Sci Rep; 2016 Feb; 6():21371. PubMed ID: 26900125
[TBL] [Abstract][Full Text] [Related]
10. Dual-modality micro-positron emission tomography/computed tomography and near-infrared fluorescence imaging of EphB4 in orthotopic glioblastoma xenograft models.
Huang M; Xiong C; Lu W; Zhang R; Zhou M; Huang Q; Weinberg J; Li C
Mol Imaging Biol; 2014 Feb; 16(1):74-84. PubMed ID: 23918654
[TBL] [Abstract][Full Text] [Related]
11. Preclinical and first-in-human-brain-cancer applications of [
Young RJ; Demétrio De Souza França P; Pirovano G; Piotrowski AF; Nicklin PJ; Riedl CC; Schwartz J; Bale TA; Donabedian PL; Kossatz S; Burnazi EM; Roberts S; Lyashchenko SK; Miller AM; Moss NS; Fiasconaro M; Zhang Z; Mauguen A; Reiner T; Dunphy MP
Neurooncol Adv; 2020; 2(1):vdaa119. PubMed ID: 33392502
[TBL] [Abstract][Full Text] [Related]
12. Detection and Delineation of Oral Cancer With a PARP1-Targeted Optical Imaging Agent.
Kossatz S; Weber W; Reiner T
Mol Imaging; 2017; 16():1536012117723786. PubMed ID: 28856922
[TBL] [Abstract][Full Text] [Related]
13. Optical Imaging of PARP1 in Response to Radiation in Oral Squamous Cell Carcinoma.
Kossatz S; Weber WA; Reiner T
PLoS One; 2016; 11(1):e0147752. PubMed ID: 26808835
[TBL] [Abstract][Full Text] [Related]
14. Solid phase radiosynthesis of an olaparib derivative using 4-[
Xu J; Chen H; Rogers BE; Katzenellenbogen JA; Zhou D
Nucl Med Biol; 2022; 114-115():65-70. PubMed ID: 36193598
[TBL] [Abstract][Full Text] [Related]
15. [
Pirovano G; Roberts S; Brand C; Donabedian PL; Mason C; de Souza PD; Higgins GS; Reiner T
Mol Imaging Biol; 2019 Aug; 21(4):705-712. PubMed ID: 30357568
[TBL] [Abstract][Full Text] [Related]
16. Discriminating radiation injury from recurrent tumor with [
Donabedian PL; Kossatz S; Engelbach JA; Jannetti SA; Carney B; Young RJ; Weber WA; Garbow JR; Reiner T
EJNMMI Res; 2018 Jul; 8(1):59. PubMed ID: 29974335
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer.
Demétrio de Souza França P; Kossatz S; Brand C; Karassawa Zanoni D; Roberts S; Guru N; Adilbay D; Mauguen A; Valero Mayor C; Weber WA; Schöder H; Ghossein RA; Ganly I; Patel SG; Reiner T
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3618-3630. PubMed ID: 33954826
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.
Persson M; Nedergaard MK; Brandt-Larsen M; Skovgaard D; Jørgensen JT; Michaelsen SR; Madsen J; Lassen U; Poulsen HS; Kjaer A
J Nucl Med; 2016 Feb; 57(2):272-8. PubMed ID: 26429955
[TBL] [Abstract][Full Text] [Related]
19. CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody.
Hernandez R; Sun H; England CG; Valdovinos HF; Ehlerding EB; Barnhart TE; Yang Y; Cai W
Theranostics; 2016; 6(11):1918-33. PubMed ID: 27570560
[TBL] [Abstract][Full Text] [Related]
20. Optical and nuclear imaging of glioblastoma with phosphatidylserine-targeted nanovesicles.
Blanco VM; Chu Z; LaSance K; Gray BD; Pak KY; Rider T; Greis KD; Qi X
Oncotarget; 2016 May; 7(22):32866-75. PubMed ID: 27096954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
